Empagliflozin – November 2022

• Brand names:
  • Jardiance®
• Pharmaceutical Company:
  • Boehringer Ingelheim Pty Ltd
• Condition/Indication: Chronic heart failure
• Meeting Date: November 2022
• Public Summary Document (PSD) November 2022 OOS 2022 PBAC Meetings - (PDF 857KB)
• Public Summary Document (PSD) November 2022 OOS 2022 PBAC Meetings - (Word 593KB)

Related Public Summary Documents

• Empagliflozin – December 2022